Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Bryant, Sanjeev Kumar, W. Spannuth, J. Shah, A. Munkarah, M. Deppe, R. Alvarez, R. Morris (2011)
Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancerArchives of Gynecology and Obstetrics, 283
P. Rose, Kim Mossbruger, N. Fusco, M. Smrekar, S. Eaton, Michael Rodriguez (2003)
Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma.Gynecologic oncology, 88 1
J. Thigpen (2010)
Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian CancerYearbook of Oncology, 2010
G. Stuart, H. Kitchener, M. Bacon, A. Dubois, M. Friedlander, J. Ledermann, C. Marth, T. Thigpen, E. Trimble (2011)
2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus ConferenceInternational Journal of Gynecologic Cancer, 21
P. Fong, D. Boss, T. Yap, A. Tutt, P. Wu, M. Mergui-Roelvink, Peter Mortimer, H. Swaisland, A. Lau, M. O’Connor, A. Ashworth, J. Carmichael, S. Kaye, J. Schellens, J. Bono (2009)
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.The New England journal of medicine, 361 2
R. Strother, D. Matei (2009)
Pegylated liposomal doxorubicin in ovarian cancerTherapeutics and Clinical Risk Management, 5
R. Verhaak, P. Tamayo, Ji-Yeon Yang, D. Hubbard, Hailei Zhang, C. Creighton, S. Fereday, M. Lawrence, S. Carter, C. Mermel, A. Kostic, D. Etemadmoghadam, G. Saksena, K. Cibulskis, S. Duraisamy, Keren Levanon, C. Sougnez, Aviad Tsherniak, Sebastian Gomez, R. Onofrio, S. Gabriel, L. Chin, Nianxiang Zhang, P. Spellman, Yiqun Zhang, R. Akbani, K. Hoadley, A. Kahn, M. Köbel, D. Huntsman, R. Soslow, A. deFazio, M. Birrer, J. Gray, J. Weinstein, D. Bowtell, R. Drapkin, J. Mesirov, G. Getz, D. Levine, M. Meyerson (2012)
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.The Journal of clinical investigation, 123 1
R. Morgan, R. Alvarez, D. Armstrong, R. Burger, Lee-may Chen, L. Copeland, M. Crispens, D. Gershenson, H. Gray, A. Hakam, L. Havrilesky, C. Johnston, S. Lele, Lainie Martin, U. Matulonis, D. O’Malley, R. Penson, M. Powell, S. Remmenga, P. Sabbatini, J. Santoso, J. Schink, N. Teng, T. Werner, M. Dwyer, M. Hughes (2013)
Ovarian cancer, version 2.2013.Journal of the National Comprehensive Cancer Network : JNCCN, 11 10
M. Parmar, J. Ledermann, N. Colombo, B. Du, JF Delaloye, G. Kristensen, S. Wheeler, A. Swart, W. Qian, V. Torri, I. Floriani, G. Jayson, A. Lamont, C. Tropé (2003)
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trialThe Lancet, 361
J. Thigpen (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian CancerYearbook of Oncology, 2012
K. Gelmon, M. Tischkowitz, H. Mackay, K. Swenerton, A. Robidoux, K. Tonkin, H. Hirte, D. Huntsman, M. Clemons, B. Gilks, R. Yerushalmi, E. Macpherson, J. Carmichael, A. Oza (2011)
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.The Lancet. Oncology, 12 9
J. Ledermann, P. Harter, C. Gourley, M. Friedlander, I. Vergote, G. Rustin, C. Scott, W. Meier, R. Shapira-Frommer, T. Safra, D. Matei, A. Fielding, S. Spencer, B. Dougherty, M. Orr, D. Hodgson, J. Barrett, U. Matulonis (2014)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialObstetrical & Gynecological Survey, 69
K. Alsop, S. Fereday, C. Meldrum, A. deFazio, C. Emmanuel, J. George, A. Dobrovic, M. Birrer, P. Webb, C. Stewart, M. Friedlander, S. Fox, D. Bowtell, G. Mitchell (2012)
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 21
E. Pujade-Lauraine, F. Hilpert, B. Weber, A. Reuss, A. Poveda, G. Kristensen, R. Sorio, I. Vergote, P. Witteveen, A. Bamias, D. Pereira, P. Wimberger, A. Oaknin, M. Mirza, P. Follana, D. Bollag, I. Ray-Coquard (2014)
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 13
M. Markman, R. Rothman, T. Hakes, B. Reichman, W. Hoskins, S. Rubin, W. Jones, L. Almadrones, J. Lewis (1991)
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 9 3
J. Thigpen (2012)
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patientsYearbook of Medicine, 2012
R. Burger, M. Sill, B. Monk, B. Greer, J. Sorosky (2007)
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 33
G. Bozas, A. Bamias, V. Koutsoukou, E. Efstathiou, D. Gika, C. Papadimitriou, M. Dimopoulos (2007)
Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma.Gynecologic oncology, 104 3
N. Colombo, E. Kutarska, M. Dimopoulos, D. Bae, I. Rzepka-górska, M. Bidziński, G. Scambia, S. Engelholm, F. Joly, D. Weber, M. El-Hashimy, Jingjin Li, F. Souami, P. Wing, S. Engelholm, A. Bamias, P. Schwartz (2012)
Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 31
(2004)
Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based
N. Katsumata, M. Yasuda, S. Isonishi, F. Takahashi, H. Michimae, E. Kimura, D. Aoki, T. Jobo, S. Kodama, F. Terauchi, T. Sugiyama, K. Ochiai (2013)
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.The Lancet. Oncology, 14 10
D. Alberts, Poching Liu, S. Wilczynski, M. Clouser, A. López, D. Michelin, V. Lanzotti, M. Markman (2007)
Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).Gynecologic oncology, 108 1
Agustin Garcia, H. Hirte, G. Fleming, Dongyun Yang, D. Tsao-Wei, L. Roman, S. Groshen, S. Swenson, F. Markland, D. Gandara, S. Scudder, R. Morgan, Helen Chen, H. Lenz, A. Oza (2008)
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 1
B. Monk (2014)
A phase III, randomized, double-blind trialof weekly paclitaxel plus the angiopoientin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1
Lars Hanker, S. Loibl, N. Burchardi, J. Pfisterer, W. Meier, E. Pujade-Lauraine, I. Ray-Coquard, J. Sehouli, P. Harter, A. Bois (2012)
The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy.Annals of oncology : official journal of the European Society for Medical Oncology, 23 10
A. Gordon, J. Fleagle, D. Guthrie, D. Parkin, M. Gore, Á. Lacave (2001)
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 14
E. Eisenhauer, J. Vermorken, M. Glabbeke (1997)
Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments].Annals of oncology : official journal of the European Society for Medical Oncology, 8 10
J. Thigpen (2008)
Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian CancerYearbook of Oncology, 2008
W. Huinink, M. Gore, J. Carmichael, A. Gordon, J. Malfetano, I. Hudson, C. Broom, C. Scarabelli, N. Davidson, M. Spanczynski, G. Bolis, H. Malmstrom, R. Coleman, S. Fields, J. Héron (1997)
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 6
G. Rustin, N. Reed, G. Jayson, J. Ledermann, M. Adams, T. Perren, C. Poole, M. Lind, M. Persic, S. Essapen, M. Gore, H. Calvert, C. Stredder, A. Wagner, M. Giurescu, S. Kaye (2011)
A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 22 11
R. Burger (2011)
Overview of anti-angiogenic agents in development for ovarian cancer.Gynecologic oncology, 121 1
M. Markman (1998)
"Recurrence within 6 months of platinum therapy": an adequate definition of "platinum-refractory" ovarian cancer?Gynecologic oncology, 69 2
R. Naumann, R. Coleman, Robert Burger, E Sausville, E. Kutarska, S. Ghamande, N. Gabrail, Stephen DePasquale, E. Nowara, L. Gilbert, R. Gersh, M. Teneriello, W. Harb, Panagiotis Konstantinopoulos, R. Penson, James Symanowski, C. Lovejoy, Christopher Leamon, David Morgenstern, R. Messmann (2013)
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 35
M. Gore, I. Fryatt, E. Wiltshaw, T. Dawson (1990)
Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.Gynecologic oncology, 36 2
E. Pujade-Lauraine, U. Wagner, E. Aavall-Lundqvist, V. Gebski, M. Heywood, P. Vasey, B. Volgger, I. Vergote, S. Pignata, A. Ferrero, J. Sehouli, A. Lortholary, G. Kristensen, C. Jackisch, F. Joly, Chris Brown, N. Fur, A. Bois (2010)
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 20
I. Vergote, H. Calvert, M. Kania, C. Kaiser, A. Zimmermann, J. Sehouli (2009)
A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer.European journal of cancer, 45 8
R. Morgan, R. Alvarez, D. Armstrong, R. Burger, Lee-may Chen, L. Copeland, M. Crispens, D. Gershenson, H. Gray, A. Hakam, L. Havrilesky, C. Johnston, S. Lele, Lainie Martin, U. Matulonis, D. O’Malley, R. Penson, M. Powell, S. Remmenga, P. Sabbatini, J. Santoso, J. Schink, N. Teng, T. Werner, M. Dwyer, M. Hughes (2013)
Ovarian cancer, version 2.2013: Featured updates to the NCCN guidelinesJournal of The National Comprehensive Cancer Network, 11
P. Rosenberg, Harriet Andersson, K. Boman, M. Ridderheim, B. Sorbe, U. Puistola, G. Parö (2002)
Randomized Trial of Single Agent Paclitaxel Given Weekly Versus Every Three Weeks and with Peroral Versus Intravenous Steroid Premedication to Patients with Ovarian Cancer Previously Treated with PlatinumActa Oncologica, 41
JS Tanguay, J. Ansari, L. Buckley, I. Fernando (2009)
Epithelial Ovarian Cancer: Role of Pegylated Liposomal Doxorubicin in Prolonging the Platinum-Free Interval and Cancer Antigen 125 Trends During TreatmentInternational Journal of Gynecologic Cancer, 19
M. Stockler, F. Hilpert, M. Friedlander, M. King, L. Wenzel, C. Lee, F. Joly, N. Gregorio, J. Arija, M. Mirza, R. Sorio, U. Freudensprung, V. Sneller, G. Hales, E. Lauraine (2013)
Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC).Journal of Clinical Oncology, 31
R. Zang, P. Harter, D. Chi, J. Sehouli, R. Jiang, C. Tropé, A. Ayhan, G. Cormio, Y. Xing, K. Wollschlaeger, E. Braicu, C. Rabbitt, H. Oksefjell, W. Tian, C. Fotopoulou, J. Pfisterer, A. Bois, J. Berek (2011)
Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohortBritish Journal of Cancer, 105
N. Colombo, M. Peiretti, G. Parma, M. Lapresa, R. Mancari, S. Carinelli, C. Sessa, M. Castiglione (2010)
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 21 Suppl 5
M. Friedlander, E. Trimble, A. Tinker, D. Alberts, E. Åvall-Lundqvist, M. Brady, P. Harter, S. Pignata, E. Lauraine, J. Sehouli, I. Vergote, P. Beale, R. Bekkers, P. Calvert, L. Copeland, R. Glasspool, A. González-Martín, D. Katsaros, Jae Kim, B. Miller, D. Provencher, L. Rubinstein, M. Atri, A. Zeimet, M. Bacon, H. Kitchener, G. Stuart (2011)
Clinical Trials in Recurrent Ovarian CancerInternational Journal of Gynecologic Cancer, 21
M. Burg, R. Wit, W. Putten, A. Logmans, W. Kruit, G. Stoter, J. Verweij (2002)
Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancerBritish Journal of Cancer, 86
N. Horowitz, Jun Hua, R. Gibb, D. Mutch, T. Herzog (2004)
The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.Gynecologic oncology, 94 1
A. Tutt, Mark Robson, Judy Garber, S. Domchek, William Audeh, J. Weitzel, M. Friedlander, B. Arun, N. Loman, R. Schmutzler, Andrew Wardley, G. Mitchell, H. Earl, M. Wickens, J. Carmichael (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialThe Lancet, 376
J. Ledermann, T. Perren, F. Raja, A. Embleton, G. Rustin, G. Jayson, S. Kaye, A. Swart, M. Vaughan, H. Hirte (2013)
Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial
Rohini Sharma, J. Graham, H. Mitchell, A. Brooks, S. Blagden, H. Gabra (2009)
Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancerBritish Journal of Cancer, 100
M. Piccart, J. Green, Á. Lacave, N. Reed, I. Vergote, P. Benedetti‐Panici, A. Bonetti, V. Kristeller-Tome, C. Fernández, D. Curran, M. Glabbeke, D. Lacombe, M. Pinel, S. Pecorelli (2000)
Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 6
T. Yap, S. Sandhu, C. Carden, J. Bono (2011)
Poly(ADP‐Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinicCA: A Cancer Journal for Clinicians, 61
F. Raja, Nicholas Counsell, N. Colombo, J. Pfisterer, A. Bois, M. Parmar, I. Vergote, A. González-Martín, David Alberts, Marie Plante, V. Torri, J. Ledermann (2013)
Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.Annals of oncology : official journal of the European Society for Medical Oncology, 24 12
Lainie Martin, T. Hamilton, R. Schilder (2008)
Platinum Resistance: The Role of DNA Repair PathwaysClinical Cancer Research, 14
S. Orsulic (1993)
Ovarian CancerBritish Journal of Cancer, 68
G. Rustin, I. Vergote, E. Eisenhauer, E. Pujade-Lauraine, M. Quinn, T. Thigpen, A. Bois, G. Kristensen, A. Jakobsen, S. Sagae, K. Greven, M. Parmar, M. Friedlander, A. Cervantes, J. Vermorken (2010)
Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)International Journal of Gynecologic Cancer, 21
D. Bell, A. Berchuck, M. Birrer, J. Chien, D. Cramer, F. Dao, R. Dhir, P. Disaia, H. Gabra, Pat Glenn, A. Godwin, J. Gross, L. Hartmann, M. Huang, D. Huntsman, M. Iacocca, M. Imieliński, S. Kalloger, B. Karlan, D. Levine, G. Mills, C. Morrison, D. Mutch, Narciso Olvera, S. Orsulic, K. Park, N. Petrelli, B. Rabeno, J. Rader, B. Sikic, K. Smith-McCune, A. Sood, D. Bowtell, R. Penny, J. Testa, K. Chang, H. Dinh, J. Drummond, G. Fowler, P. Gunaratne, A. Hawes, C. Kovar, L. Lewis, M. Morgan, I. Newsham, J. Santibanez, J. Reid, L. Treviño, Y. Wu, M. Wang, D. Muzny, D. Wheeler, R. Gibbs, G. Getz, M. Lawrence, K. Cibulskis, A. Sivachenko, C. Sougnez, Douglas Voet, Jane Wilkinson, Toby Bloom, K. Ardlie, T. Fennell, J. Baldwin, S. Gabriel, E. Lander, L. Ding, R. Fulton, D. Koboldt, M. McLellan, T. Wylie, Jason Walker, M. O'Laughlin, D. Dooling, L. Fulton, R. Abbott, N. Dees, Q. Zhang, C. Kandoth, M. Wendl, W. Schierding, D. Shen, C. Harris, H. Schmidt, Joelle Kalicki, K. Delehaunty, C. Fronick, Ryan Demeter, L. Cook, J. Wallis, L. Lin, V. Magrini, J. Hodges, James Eldred, S. Smith, C. Pohl, Fabio Vandin, Benjamin Raphael, G. Weinstock, E. Mardis, R. Wilson, M. Meyerson, W. Winckler, R. Verhaak, Suzie Carter, C. Mermel, G. Saksena, H. Nguyen, R. Onofrio, D. Hubbard, S. Gupta, A. Crenshaw, A. Ramos, L. Chin, A. Protopopov, Juinhua Zhang, T. Kim, I. Perna, Y. Xiao, Hailei Zhang, G. Ren, N. Sathiamoorthy, R. Park, E. Lee, P. Park, R. Kucherlapati, D. Absher, L. Waite, G. Sherlock, J. Brooks, Jun Li, Jin Xu, R. Myers, P. Laird, L. Cope, J. Herman, Hui Shen, D. Weisenberger, H. Noushmehr, F. Pan, T. Triche, B. Berman, D. Berg, J. Buckley, S. Baylin, P. Spellman, E. Purdom, P. Neuvial, H. Bengtsson, L. Jakkula, S. Durinck, J. Han, S. Dorton, H. Marr, Y. Choi, V. Wang, Ninghai Wang, J. Ngai, J. Conboy, B. Parvin, H. Feiler, T. Speed, J. Gray, N. Socci, Yanke Liang, B. Taylor, N. Schultz, L. Borsu, A. Lash, C. Brennan, A. Viale, C. Sander, M. Ladanyi, K. Hoadley, S. Meng, Y. Du, Yufeng Shi, Lulin Li, Y. Turman, D. Zang, E. Helms, S. Balu, X. Zhou, Jinhua Wu, M. Topal, D. Hayes, C. Perou, Jun Zhang, Chaowei Wu, S. Shukla, A. Sivachenko, R. Jing, Yueh-Feng Liu, M. Noble, H. Carter, D. Kim, R. Karchin, J. Korkola, Laura Heiser, R. Cho, Zhihao Hu, E. Cerami, A. Olshen, B. Reva, Yevgeniy Antipin, R. Shen, P. Mankoo, R. Sheridan, G. Ciriello, William Chang, J. Bernanke, D. Haussler, C. Benz, Joshua Stuart, S. Benz, J. Sanborn, Charles Vaske, Jiangyu Zhu, C. Szeto, G. Scott, C. Yau, M. Wilkerson, N. Zhang, R. Akbani, K. Baggerly, W. Yung, J. Weinstein, T. Shelton, D. Grimm, M. Hatfield, S. Morris, P. Yena, P. Rhodes, M. Sherman, J. Paulauskis, S. Millis, A. Kahn, J. Greene, R. Sfeir, M. Jensen, James Chen, J. Whitmore, S. Alonso, J. Jordan, A. Chu, Jinghui Zhang, A. Barker, C. Compton, G. Eley, M. Ferguson, P. Fielding, D. Gerhard, R. Myles, C. Schaefer, K. Shaw, J. Vaught, J. Vockley, P. Good, M. Guyer, B. Ozenberger, James Peterson, E. Thomson (2011)
Integrated Genomic Analyses of Ovarian CarcinomaNature, 474
J. Ledermann, P. Harter, C. Gourley, M. Friedlander, I. Vergote, G. Rustin, Clare Scott, W. Meier, R. Shapira-Frommer, T. Safra, D. Matei, A. Fielding, S. Spencer, B. Dougherty, M. Orr, D. Hodgson, J. Barrett, U. Matulonis (2014)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.The Lancet. Oncology, 15 8
C. Aghajanian, S. Blank, B. Goff, P. Judson, M. Teneriello, A. Husain, M. Sovak, J. Yi, L. Nycum (2011)
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 17
D. Pinato, J. Graham, H. Gabra, Rohini Sharma (2013)
Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance.Cancer treatment reviews, 39 2
R. Kerbel, B. Kamen (2004)
The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 4
R. Carlson (2012)
Platinum-Resistant Ovarian Cancer: Bevacizumab Extends PFS
Yong Han, Hao Huang, Zhen Xiao, Wei Zhang, Yanfei Cao, L. Qu, C. Shou (2012)
Integrated Analysis of Gene Expression Profiles Associated with Response of Platinum/Paclitaxel-Based Treatment in Epithelial Ovarian CancerPLoS ONE, 7
M. Audeh, J. Carmichael, R. Penson, M. Friedlander, B. Powell, K. Bell-McGuinn, C. Scott, J. Weitzel, A. Oaknin, N. Loman, K. Lu, R. Schmutzler, U. Matulonis, M. Wickens, A. Tutt (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialThe Lancet, 376
PhD MD, M. Hahmann, PhD MD, PhD MD, PhD MD, PhD MD, PhD MD, PhD MD, PhD MD, PhD MD, PhD MD, PhD MD, PhD MD, PhD MD, PhD MD, PhD MD, PhD MD, PhD MD, PhD MD, PhD MD (2009)
Surgery for Recurrent Ovarian Cancer: Role of Peritoneal Carcinomatosis: Exploratory Analysis of the DESKTOP I Trial About Risk Factors, Surgical Implications, and Prognostic Value of Peritoneal CarcinomatosisAnnals of Surgical Oncology, 16
J. Thigpen (2008)
Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCGYearbook of Oncology, 2008
W. Meier, A. Bois, A. Reuss, W. Kuhn, S. Olbricht, M. Gropp, B. Richter, H. Lück, R. Kimmig, J. Pfisterer (2009)
Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGynecologic oncology, 114 2
S. Kaye, N. Colombo, B. Monk, S. Tjulandin, B. Kong, M. Roy, Stephen Chan, E. Filipczyk-Cisarż, H. Hagberg, I. Vergote, C. Lebedinsky, T. Parekh, P. Santabarbara, Youn Park, Antonio Nieto, A. Poveda (2010)
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free intervalAnnals of Oncology, 22
J. Kavanagh, D. Tresukosol, C. Edwards, R. Freedman, C. León, A. Fishman, R. Mante, M. Hord, A. Kudelka (1995)
Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 7
Walter Gotlieb, F. Amant, S. Advani, C. Goswami, H. Hirte, D. Provencher, N. Somani, S. Yamada, J. Tamby, I. Vergote (2012)
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.The Lancet. Oncology, 13 2
G. McCann, Blair Smith, F. Backes, K. Rath, Simi Chacko, R. Salani, E. Eisenhauer, J. Fowler, D. Cohn, D. O’Malley (2012)
Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?Gynecologic oncology, 127 2
G. Bolis, G. Scarfone, G. Giardina, A. Villa, G. Mangili, M. Melpignano, M. Presti, S. Tateo, M. Franchi, F. Parazzini (2001)
Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.Gynecologic oncology, 81 1
D. Bafaloukos, H. Linardou, G. Aravantinos, C. Papadimitriou, A. Bamias, G. Fountzilas, H. Kalofonos, P. Kosmidis, E. Timotheadou, T. Makatsoris, E. Samantas, E. Briasoulis, C. Christodoulou, P. Papakostas, D. Pectasides, A. Dimopoulos (2010)
A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group studyBMC Medicine, 8
J. Dungan (2011)
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trialYearbook of Obstetrics, Gynecology and Women's Health, 2011
Ovarian cancer (OC) is the fifth most common cause of cancer death in women. Although significant progress has been made in the treatment of OC, the majority of patients experience disease recurrence and receive second-line and sometimes several lines of treatment. Here we review the options available for the treatment of recurrent disease and discuss how different agents are selected, combined and offered in a rationale sequence in the context of multidisciplinary care. We reviewed published work between 1990 and 2013 and meeting abstracts related to the use of chemotherapy and surgery in patients with recurrent ovarian cancer. We discuss treatment regimens, efficacy endpoints and safety profiles of the different therapies. Platinum-based drugs are the most active agents and are selected on the basis of a probability of response to retreatment. Nonplatinum-based chemotherapy regimens are usually given in the ‘platinum-resistant’ setting and have a modest effect on outcome. Molecular targeted therapy of ovarian cancer given alone or integrated with chemotherapy is showing promising results. Many patients are now receiving more than one line of therapy for recurrent disease, usually platinum based until platinum resistance emerges. The sequential use of chemotherapy regimens and the incorporation of molecularly targeted treatments, either alone or in combination with chemotherapy, have over the last decade significantly extended the median survival of patients with ovarian cancer.
Therapeutic Advances in Medical Oncology – SAGE
Published: Aug 5, 2014
Keywords: bevacizumab,poly-ADP ribose polymerase inhibitors,platinum resistant,platinum sensitive,relapsed ovarian cancer
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.